AutoGenomics Introduces INFINITI® SMART – Sample-to-Result NextGen Automation Platform – at AACC 2015
Vista, CA -- AutoGenomics, Inc., a leader in providing automated molecular testing solutions to clinical laboratories, announced today that it will showcase its “Sample-to-Result” NextGen automation platform – INFINITI® SMART – at the American Association for Clinical Chemistry Meeting (AACC) in Atlanta, to be held from July 28 – 30, 2015.
INFINITI® SMART is a fully automated “walk-away” system designed to eliminate the need for sample extraction and automate all the discrete steps in genetic testing. Samples such as blood and buccal swabs can be processed directly on the instrument. This fully integrated multiplexing high volume system will analyze up to 48 individual samples simultaneously.
The addition of the INFINITI® SMART to the existing AutoGenomics’ family of INFINITI® Analyzers – INFINITI® Plus and the INFINITI® High Throughput System – will further open the molecular diagnostic testing market to small, medium and high volume testing laboratories.
AutoGenomics expects to initially offer a menu of 11 tests with the INFINITI® SMART including pharmacogenomics tests for CYP2D6, 2C19, 2C9-VKORC1, 3A4, 3A5, Apo E, Factor II, Factor V, MTHFR, Flu and HCV genotyping. AutoGenomics intends to obtain FDA 510(k) clearance for these tests.
“By offering total automation and eliminating the need for instrumentation such as sample extraction units and thermocyclers, we are focusing on meeting key customer needs to lower the cost per reportable result and enhance productivity in the lab,” said Fareed Kureshy, President and Chief Executive Officer of AutoGenomics.
AutoGenomics Inc., a privately held company based in Vista, CA, developed the first automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the area of pharmacogenomics, genetic disorders, infectious disease and cancer. With the discovery of genes and their link to various disease states, the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed, leading to the era of precision medicine. www.autogenomics.com.
President and Chief Executive Officer
(760) 477-2248 ext. 306